High intratumoral Galectin-1 expression predicts adverse outcome in ALK- ALCL and CD30+ PTCL-NOS.
Galectin-1 (Gal-1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression. However, Gal-1 expression has not been systematically assessed in peripheral T-cell lymphomas (PTCL). Specimens from 169 nodal PTCL were assessed for intratumoral Gal-1 expression by immunohistochemistry. Overall survival (OS) in groups exhibiting high and low Gal-1 expression was compared in the cohort and in a subset analysis of CD30-positive PTCL only. Gal-1 expression was also correlated with biomarkers of the tumor microenvironment. No significant difference in OS based on Gal-1 expression was observed in the entire PTCL cohort. However, in the CD30-positive cohort, patients with high Gal-1 levels had significantly poorer outcome (5 years OS 10%, 95% confidence interval (CI): 1-36) than their low Gal-1 counterparts (5 years OS 48%, 95%CI: 30-64, P=0.021). In univariate analyses age≤60, non-elevated LDH, and performance score<2 correlated with superior survival but high Gal-1 expression significantly predicted adverse outcome at both univariate (HR 2.5, 95%CI: 1.1-5.7, P=0.026) and multivariate levels (HR 3.2, 95%CI: 1.2-8.5, P=0.017). Tumors with high Gal-1 had few cytotoxic T cells in the tumor microenvironment. High intratumoral Gal-1 expression before therapeutic intervention correlates with adverse outcome in nodal CD30+ , ALK- PTCL patients. This article is protected by copyright. All rights reserved.